Zoom in

In times when diabetes mellitus is ranked among the pandemics of the 21st century for being one of the staunchest non-transmissible chronic diseases worldwide, Heberprot-P® and the therapy related to this medicine have become a true milestone with specific answers to tackle one of the most frequent problems linked to this disease: diabetic foot ulcers.
Heberprot-P®, developed by the Genetic Engineering and Biotechnology Center (CIGB is the Spanish acronym), combined with the treatment that supports and validates it from a medical approach, successfully cuts down on amputation risk in a staggering 78 percent of patients, thus shortening scarring periods and helping them recover faster.
So far, over 300,000 people have benefited from this new therapy, both in Cuba –where the program is applied in the country’s three-tier healthcare system- and in other nations by means of over twenty sanitary licenses and 30 patents of the product.
Diabetic patients around the world can presently have access to that therapeutic alternative by contacting Comercializadora de Servicios Médicos Cubanos, S.A. –through its diverse promotion and sale outlets- and by asking for the corresponding assessment of their case.
Moreover, Cuba offers the international market and patients visiting the country a comprehensive medical program to monitor and control this disease, in an effort to improve their quality of life and reduce the frequency and severity of intense and chronic complications.